Home » Newsletters » BioWorld Science

BioWorld Science

March 19, 1998

View Archived Issues

Estrogen: a potential agent for prevention of dementia?

COX-1 inhibition is more effective than COX-2 inhibition in a chronic inflammation model

Company Profile: Sinogen

Dusa: year-end 1997 highlights

Potent inhibitors of IL-1beta and TNF-alpha production prepared at Nisshin Flour Milling

Abbott describes novel lead structure for selective COX-2 inhibitors

AHP reports novel neuroprotectants

Company Profile: SuperGen

U.S. university scientists report novel muscarinic agonists

BB-10010 has myelosuppressive and progenitor cell-mobilizing effects in humans

LXR files IND for CP-Cardiosol

Analysis of statin results confirms beneficial clinical effects of lipid lowering on mortality

Phase II ImmTher trial begins in pediatric cancer patients

FDA clears free PSA blood test

LifeCell will be awarded U.S. patent for blood cell preservation technology

Mechanism of chemopreventive activity of resveratrol identified

GABA-A receptor ligands under evaluation at Neurogen

Ixion succeeds in lowering urinary oxalate levels with IxC1-62/47

Creative BioMolecules: year-end 1997 highlights

Fuisz closes acquisition of Rentschler

SmithKline Beecham and Ligand begin leptin-obesity collaboration

Spongiform encephalopathies advisory committee meeting scheduled

Collagenex amends NDA for Periostat

Roche benzodiazepines go head-to-head with midazolam

CytRx begins patient enrollment for Flocor phase III trial

Combivir approved in E.U.

Novel enzyme inhibitors discovered at California institute

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Sept. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Sept. 18, 2025.
‘Prolific’ Regeneron won’t stop with phase III FOP data drop
BioWorld
“People have some inability to focus on [Regeneron Pharmaceuticals Inc.’s] pipeline,” which stands as “the most prolific in the industry, I would dare to say,”...
The ‘molecular revolution’ driving R&D of new cancer therapeutics
BioWorld Asia
“New explosions in biotechnology are allowing us to interrogate cancers at a very sophisticated level compared to before,” Dennis Slamon told audience members at...
Remynd’s REM-127 yields positive phase II data in Alzheimer’s
BioWorld
Remynd NV has turned in positive phase IIa data for a new target in Alzheimer’s disease, showing that restoring calcium homeostasis in neurons reduces levels of...